A clinician's guide to biosimilars in oncology

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Biological agents (biologics) are crucial in oncology for cancer treatment and managing side effects.
• Exact copies of biologics are not feasible due to their complex nature, necessitating the development of biosimilars.

Purpose of the Study:

• To inform oncology practitioners about the development and evaluation of biosimilars.
• To provide guidance on assessing biosimilar data for informed clinical decision-making.
• To review biosimilars currently in development for cancer treatment.

Main Methods:

• The article reviews the regulatory framework and scientific principles governing biosimilar development.
• It outlines the analytical, clinical, and non-clinical studies required for biosimilar approval.
• Guidance is provided on interpreting comparative data to establish biosimilarity.

Main Results:

• Biosimilars are demonstrated to be highly similar to reference products in terms of safety, purity, and potency.
• The development process ensures no clinically meaningful differences compared to the originator biologic.
• Upcoming biosimilars for rituximab, trastuzumab, and bevacizumab are expected.

Conclusions:

• Biosimilars represent a significant opportunity to enhance access to essential biologic therapies in oncology.
• Oncologists can confidently integrate biosimilars into practice by understanding the rigorous evaluation process.
• The adoption of biosimilars is anticipated to yield substantial healthcare savings and improve global patient outcomes.